Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Silo Pharma Inc
(NQ:
SILO
)
0.9800
-0.0083 (-0.84%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jun 21, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Silo Pharma Inc
< Previous
1
2
3
4
5
Next >
Silo Pharma’s SPC-15 Awarded U.S. Patent to Protect Ongoing R&D of Therapeutic for Stress-Induced Affective Disorder and Alzheimer’s Disease
May 09, 2023
ENGLEWOOD CLIFFS, NJ – May 9, 2023 – Silo Pharma, Inc. (NASDAQ: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic...
Via
FinancialNewsMedia
Topics
Intellectual Property
Exposures
Intellectual Property
Silo Pharma’s SPC-15 Awarded U.S. Patent Protecting Ongoing R&D of Therapeutic for Stress-Induced Affective Disorder and Alzheimer’s Disease
May 09, 2023
From
Silo Pharma, Inc.
Via
GlobeNewswire
InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Announces Participation at Upcoming Psychedelic Drug Development Conference
April 24, 2023
Via
Investor Brand Network
Silo Pharma to Present at Psychedelic Drug Development Conference
April 24, 2023
From
Silo Pharma, Inc.
Via
GlobeNewswire
InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Begins Development of Treatment for Anxiety-Related Disorders
April 19, 2023
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
Silo Pharma Commences Formulation for SPC-15 Targeting Anxiety and PTSD Stress-Related Disorders
April 19, 2023
ENGLEWOOD CLIFFS, NJ – April 19, 2023 – Silo Pharma, Inc. (NASDAQ:SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic...
Via
FinancialNewsMedia
Silo Pharma Commences Formulation for SPC-15 Targeting Anxiety and PTSD Stress-Related Disorders
April 19, 2023
Data to Support Alzheimer’s Study
From
Silo Pharma, Inc.
Via
GlobeNewswire
Silo Pharma Inc. (NASDAQ: SILO) Provides Update on Innovative Study Looking into the Feasibility of Using Ketamine Formulations as an Alternative Treatment for Fibromyalgia
March 28, 2023
Via
Investor Brand Network
PsychedelicNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Files Patent for Treatment of Fibromyalgia
March 27, 2023
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
Product Safety
Silo Pharma Announces filing of Patent for Treatment of Fibromyalgia
March 27, 2023
From
Silo Pharma, Inc.
Via
GlobeNewswire
PsychedelicNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Positioned as Frontrunner in Psychedelic Drugs Market
March 24, 2023
Via
Investor Brand Network
PsychedelicNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Announces Positive Results from IND-Enabling Toxicology Study of SP-26
March 15, 2023
Via
Investor Brand Network
Exposures
Product Safety
Silo Pharma Announces Positive Results from IND-Enabling Study of SP-26 for Fibromyalgia
March 15, 2023
From
Silo Pharma, Inc.
Via
GlobeNewswire
Silo Pharma Inc. (NASDAQ: SILO) Set to Benefit as Study Supports the Efficacy of Psychedelics in Treating ‘Drug-Resistant’ Depression
March 13, 2023
Via
Investor Brand Network
Exposures
COVID-19
PsychedelicNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Expands Intellectual Property, Technology Rights for Treating Rare Stress-Related Medical Conditions
March 03, 2023
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
Silo Pharma Inc. (NASDAQ: SILO) Granted US Patent For SPC-15 to Prevent and Treat Stress-Induced Disorders
February 22, 2023
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
BioMedNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Files Patent for Treatment of Alzheimer’s
February 13, 2023
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
Silo Pharma Announces Filing of Patent for Treatment of Alzheimer’s
February 13, 2023
From
Silo Pharma, Inc.
Via
GlobeNewswire
BioMedNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Partnering to Transform Health Care, Improve Patient Outcomes
February 07, 2023
Via
Investor Brand Network
PsychedelicNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Expands IP Portfolio with New USPTO Patent
February 02, 2023
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
Silo Pharma Announces Expansion of Intellectual Property Portfolio
February 02, 2023
Silo Receives Issuance of U.S. Patent Covering SPC-15 Method for Treatment and Prevention of Stress-Induced Affective Disorders
From
Silo Pharma, Inc.
Via
GlobeNewswire
PsychedelicNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Board Authorizes Stock Repurchase Program
January 31, 2023
Via
Investor Brand Network
Silo Pharma Announces Stock Repurchase Program
January 31, 2023
From
Silo Pharma, Inc.
Via
GlobeNewswire
Silo Pharma Inc. (NASDAQ: SILO) Provides Update on UCSF Psylocibin Clinical Trial
January 26, 2023
Via
Investor Brand Network
PsychedelicNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Eying Broad Market Opportunities for Its Liposomal Joint Homing Peptide
January 20, 2023
Via
Investor Brand Network
Silo Pharma Inc. (NASDAQ: SILO) Provides Positive Update on Ongoing Study into the Use of Joint Homing Peptides as an Alternative Treatment for Rheumatoid Arthritis
January 12, 2023
Via
Investor Brand Network
InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Advances Clinical Study Examining Psilocybin’s Effect on Inflammation
January 10, 2023
Via
Investor Brand Network
Silo Pharma Advances Clinical Study Analyzing Effects of Psilocybin on Inflammation
January 10, 2023
From
Silo Pharma, Inc.
Via
GlobeNewswire
InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Reports Positive Results from SPU- 21 Arthritis Study
January 03, 2023
Via
Investor Brand Network
Silo Pharma (NASDAQ: SILO) Reports Positive Results from Dose Optimization Study for SPU-21 and Treatment of Arthritis
December 30, 2022
Silo Pharma, Inc. (NASDAQ: SILO) operates as a development-stage biopharmaceutical company, which is focused on combining traditional therapies with psychedelics
Via
Spotlight Growth
< Previous
1
2
3
4
5
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.